Acute treatement of Migraine with or without aura.
Selective Serotonin (5HT1) Agonists; Antimigrairie drug
Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides through nerve endings in the trigeminal system. The therapeutic activity of Zolmitriptan for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system which results in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
2.5 mg if symptoms persist or return within 24 hours, a second dose has been shown to be effective within 2 hours of the initial dose, subsequent attacks can be treated with 5 mg doses of Nomi (Zolmitriptan).
Known hypersensitivity, uncontrolled hypertension. Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathways.
Not serious, nausea; dizziness; somnolence; warm sensation; asthenia; dry mouth, heaviness, tightness or pressure may occur in the throat, neck, limbs & chest (with no evidence of ischaemic changes on ECG), & myalgia, muscle weakness, paraesthesia & dysaesthesia.
Embryolethality and fetal abnormalities including malformations and variations has been demonstrated in reproductive toxicity studies in rats and rabbits at clinically relevant exposures. There are no adequate and well-controlled studies in pregnant women. Infant exposures should be minimized by avoiding breast-feeding for 24 hours after treatment.
Protect from light and moisture, store below 30°C. Keep the medicine out of the reach of children.
.png&w=384&q=75)